Relapse Clinical Trial
Official title:
A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination With Azacitidine in Subjects With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
The primary objectives are to assess the safety and tolerability profile, determine the maximum tolerated dose (MTD), and/or the recommended Phase 2 dose (RP2D) of LP-108 administered daily as a single agent dosed orally and in combination with azacitidine at 75 mg/m2 in adult subjects with relapsed/refractory MDS/CMML/AML; to characterize the pharmacokinetics (PK) profile of LP-108 as monotherapy and in combination with azacitidine in adult subjects with relapsed/refractory MDS/CMML/AML. Secondary objectives are to evaluate preliminary efficacy regarding the effect of LP-108 (monotherapy or combination therapy) on ORR for AML, MDS, CMML, PFS, DOR, and OS ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT00306813 -
Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
Completed |
NCT01956695 -
Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT05926167 -
Observational Trial Evaluating Elevated Factor VIII Related Labs as a Biomarker for Incomplete Relapse Recovery
|
||
Recruiting |
NCT03710512 -
Evaluation of Early Relapse After Mandibular Lengthening Surgery
|
||
Recruiting |
NCT04921540 -
Ingrown Toenails : Surgery Only Versus Surgery + Chemical Cauterization With TCA
|
N/A | |
Not yet recruiting |
NCT03830827 -
MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users
|
Phase 4 | |
Completed |
NCT05250765 -
Comparison of Efficiency and Effectiveness of Two Types of Bonded Orthodontic Retainers: an RCT.
|
N/A | |
Completed |
NCT05915273 -
Relapse and Failure Rates Between CAD/CAM and Conventional Fixed Retainers
|
N/A | |
Active, not recruiting |
NCT04389879 -
CAD/CAM Fixed Retainers vs. Conventional Multistranded Fixed Retainers in Orthodontic Patients. Comparison of Stability, Retainer Failure Rate, Adverse Effects, Cost-effectiveness, and Patient Satisfaction. A Randomized Controlled Clinical Trial
|
N/A | |
Recruiting |
NCT06417359 -
Comparison of Mesh Fixation and Non-Fixation in eTEP
|
N/A | |
Recruiting |
NCT06417346 -
Comparison of Laparoscopic and Open Inguinal Hernia Repair in Elderly Patients
|
N/A | |
Completed |
NCT02145403 -
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01481701 -
A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma
|
Phase 2 | |
Recruiting |
NCT01941394 -
Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation
|
Phase 2 | |
Recruiting |
NCT04723901 -
Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04994626 -
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
|
Phase 2 | |
Recruiting |
NCT06292364 -
Comparison of Retention Characteristics of Immediate vs Delayed Retainer Delivery Using 3D Digital Model Analysis
|
N/A | |
Enrolling by invitation |
NCT05591703 -
Clinical Outcomes Following Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention: A Long-term Follow-up Study
|
||
Active, not recruiting |
NCT00299923 -
Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy
|
Phase 3 |